The biotechnology company Microomics, a member of Catalonia.health, has announced a restructure of its executive team in order to embark on a new growth phase.
Co-founder, and current CEO, Pedro González Torres will take on the role of Chief Scientific Officer (CSO), leading the company’s scientific and technical strategy, driving the development of new services and metagenomic solutions. This will expand the portfolio and consolidate Microomics’ position as a key partner in microbiome analysis.
Having guided the company from its beginnings to become a leading business, Pedro is handing over executive leadership to Jordi Navarro Oller, who joined as CEO last March. Jordi has 30 years’ experience in the healthcare and life sciences industry, having developed his career at companies including Bio-Rad, Amersham Pharmacia Biotech, Siemens Healthineers and Grifols. His strong track record in commercial leadership, both nationally and internationally, will be instrumental in accelerating Microomics’ expansion into new markets.
Pedro González, new CSO at Microomics, highlights: "Jordi brings a strategic and commercial experience that will be fundamental to open new growth opportunities and international projection for Microomics. As Chief Scientific Officer, I will focus on leading scientific and technical innovation and further developing solutions that respond to the needs of our customers."
Jordi Navarro, CEO at Microomics, said: "Joining Microomics is an exciting challenge. Metagenomics is a key tool to better understand the microbial world and its impact on health, agriculture, and the environment. I am convinced that, with the scientific talent of the team and a clear strategy, we can accelerate the growth of Microomics, driving innovation and expanding our presence in new markets".
Comments